Study identifier:D0816R00006
ClinicalTrials.gov identifier:NCT02406235
EudraCT identifier:N/A
CTIS identifier:N/A
Evaluating a Novel Onco-genetic BRCA testing Counselling Model Among Patients with Ovarian Cancer - ENGAGE study
epithelial ovarian/fallopian tube/primary peritoneal cancer
N/A
No
-
All
710
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2017 by AstraZeneca
AstraZeneca
Optum
The overall objective of this study is to assess turnaround time, pre-BRCA test onco-genetic counselling quality and satisfaction with a new onco-genetic BRCA testing model.
This will be a prospective observational study of patients diagnosed with epithelial ovarian/fallopian tube/primary peritoneal cancer prior to, or at enrolment in this study. The study is descriptive in nature and does not attempt to test any specific a priori hypotheses. Clinical teams (physicians and nurses) will be trained to discuss BRCA testing with ovarian cancer patients who meet study criteria and consent to participate in the study. Patients will be recruited from participating sites in North America and Europe. Patients selected per the study inclusion and exclusion criteria will be consented for participation in the study. Patients will be recruited during an estimated 12 month period and participating patients will be followed from enrollment in the study until provision of BRCA test results, final genetics counselling, and completion of satisfaction survey or death. A case report form will be developed to collect information on the primary variable of interest (i.e., turnaround time), patient and disease characteristics, medical history, treatment patterns and outcome of the BRCA test. In addition, a survey will be developed to evaluate patient’s assessment of pre- BRCA onco-genetic counseling quality and satisfaction with onco-genetic testing process. Finally, surveys will be developed to evaluate oncologist (or oncology nurse) and genetic counselor’s assessment of the processes associated with the onco-genetic testing pathway.
Location
Location
Bronx, NY, United States
Location
Hackensack, NY, United States
Location
Providence, RI, United States
Location
Sarasota, FL, United States
Location
Mineola, NY, United States
Location
Lake Success, NY, United States
Location
Gainesville, FL, United States
Location
Chapel Hill, NC, United States
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.